Abstract
Introduction

The rising prevalence of diabetes mellitus requires new approaches to prevent the onset of diabetes among high-risk populations. Hypertension is commonly complicated by insulin resistance and type 2 diabetes. Several antihypertensive agents such as diuretics and ␤-adrenergic blockers may worsen insulin sensitivity and impair glucose tolerance; however, angiotensin II receptor blockers (ARBs) exert beneficial effects in hypertensives such as improving
insulin sensitivity and preventing the onset of diabetes [1] . Some ARBs, such as telmisartan, can effectively activate the peroxisome proliferator activated receptor ␥␥ (PPAR-␥), a key regulator of adipocyte differentiation and adipose insulin sensitivity [2] . [3] . In addition to pharmacological treatments, exercise plays an important role in the prevention of hypertension and diabetes. Skeletal muscle is the main tissue that is critical not only in endurance exercise but also in controlling glucose homeostasis. Recent studies have shown that PPAR-␦ and AMPK regulate the metabolic and contractile characteristics of myofibres [4] . PPAR-␦ overexpressing mice have a predominance of oxidative type I muscle fibres, enhanced whole-body insulin sensitivity, and greater endurance [5] . Activation of AMPK improved mouse exercise performance by 44% over that in controls [4] . Thus 
However, PPAR-␥ is rarely expressed in skeletal muscle. By contrast, PPAR-␦ (also referred to as PPAR-␤) is expressed in a wide variety of tissues, with high levels in skeletal muscle
Materials and methods
Animals and experimental procedures
Primary culture of skeletal muscle cells
Primary cultures of skeletal muscle cells were prepared as described previously [6] 
Metachromatic fibre typing of skeletal muscle
Fibre typing was performed with cryostat sections of the gastrocnemius muscle using the metachromatic dye-ATPase method as described previously [7] . (Fig. 1A-D) .
Results
Telmisartan enhances PPAR-␦ expression in cultured myotubes
Telmisartan up-regulates p-AMPK levels through PPAR-␦
We found that telmisartan significantly increased phospho-AMPK ␣ levels in cultured myotubes from wild-type mice but not in those from PPAR-␦-deficient mice ( Fig. 2A) . Importantly, telmisartan had no effect on AT1 receptor expression in cultured myotubes from either wild-type or PPAR-␦-deficient mice (Fig. 2B ). (Fig. 3A and C) . PPAR-␥ mRNA and protein levels in skeletal muscle were unaffected in PPAR-␦-deficient mice treated with or without telmisartan ( Fig. 3B and C) . (Fig. 4A and B) . Furthermore, telmisartan significantly reduced the weight of visceral and subcutaneous fat in wild-type mice, but this effect was absent in PPAR-␦-deficient mice ( Fig. 4G and H). Food intake was not affected in either group (Fig. 4C) . Also serum insulin, triglyceride and glucose levels did not differ between mouse strains with or without telmisartan treatment (Fig. 4D-F) . Fig. 5A and B) . Fig. 5A and B) .
Chronic treatment with telmisartan increases PPAR-␦ expression in skeletal muscle
Effect of telmisartan on metabolic profile in vivo
Telmisartan enhances AMPK phosphorylation through PPAR-␦ in skeletal muscle
Results in vitro showed that up-regulation of phospho-AMPK ␣ levels by telmisartan occurred in a PPAR-␦-dependent manner. Long-term administration of telmisartan increased phospho-AMPK ␣ protein levels in skeletal muscle of wild-type mice (P Ͻ 0.05), but not in that of PPAR-␦-deficient mice (
Interestingly, telmisartan did not influence AT1 receptor expression in skeletal muscle from either wild-type or PPAR-␦-deficient mice (
Chronic telmisartan treatment enhances running endurance, reduces fat mass and remodels myofibres
Skeletal muscle fibres are generally classified as type I (oxidative/slow) or type II (glycolytic/fast) fibres. Recent studies showed that PPAR-␦/AMPK activation induces a transformation from fast glycolytic to slow oxidative fibres [4, 5]. To determine whether telmisartan has a similar effect, we assessed running time, running distance, basal and post-exercise oxygen consumption. Compared with control mice, wild-type mice treated with telmisartan
Fig. 3 Long-term telmisartan intervention increases PPAR-␦, but not PPAR-␥ expression in mice skeletal muscle. mRNA (A) and protein (C) levels of PPAR-␦ and PPAR-␥ in skeletal muscle tissue from wild-type mice (WT) by Western blotting or semi-quantitative RT-PCR. mRNA (B) and protein (D) levels of PPAR-␦ and PPAR-␥ in skeletal muscle tissue from PPAR-␦-deficient mice (PPAR-␦ Ϫ/-) were analysed by Western blotting or semiquantitative RT-PCR. Mice were fed a regular diet (Cont) or a telmisartan-containing diet (Tel) for 24 weeks before being killed. *P Ͻ 0.05, **P Ͻ 0.01 versus Cont (n ϭ 4 for each group).
had greater running endurance and more post-exercise oxygen consumption (Fig. 6A-D) . Fig. 5A and B) . [9] [10] [11] . [12] [13] [14] . From a clinical perspective, these studies form the basis of a new strategy to reduce the ongoing epidemic and burden of type 2 diabetes. However, the mechanisms whereby inhibition of the rennin-angiotensin system improves glucose homeostasis are complex. They may include improvement of blood flow through the microcirculation of skeletal muscles, protection of the pancreatic islets from glucotoxicity and restoration of ␤-cell mass, and inhibition of oxidative stress [15] [16] [17] [18] . In addition, ARBs are known to activate PPAR-␥, which is responsible for their insulin-sensitizing effects [19] . PPAR-␥ is abundant in adipose tissues, functioning as the key transcription factor for adipocyte differentiation and lipid storage [10] . However, PPAR-␦ is the predominant PPAR isoform in skeletal muscle [3] . Activation of PPAR-␦ causes several changes in metabolism, including enhanced fatty acid oxidation, improved lipid profiles and reduced adiposity [20, 21] . It also regulates CB1 expression in adipose tissue [22] , increases glucose metabolism and promotes gene regulatory responses in cultured human skeletal muscle [6, 23] . Muscle-specific PPAR-␦ overexpression results in a profound change in fibre composition due to hyperplasia and/or a shift to more oxidative fibres, resulting in increased enzymatic activity and running endurance [5] .
However, PPAR-␦-deficient mice treated with telmisartan displayed no phenotypic change relative to untreated PPAR-␦-deficient mice. The skeletal muscle mass was not different between mice with and without telmisartan treatment (Fig. 6E), but the ratio of skeletal muscle weight to whole body weight was significantly higher in mice treated with telmisartan than untreated mice (Fig 6F). We further analysed the myofibre composition of gastrocnemius muscle and found that the proportion of type I slow fibres was significantly higher in telmisartantreated wild-type mice than in control wild-type mice, whereas there were no difference between two groups of PPAR-␦-deficient mice (Fig. 6G and H). In accordance with the fibre composition, the biomarker for slow skeletal muscle fibre (troposin I-ss) was significantly up-regulated in wild-type mice receiving telmisartan but not in telmisartan-treated PPAR-␦-deficient mice (
Discussion
Previous studies have highlighted a potential role for ARBs in activation of PPAR-␥ in adipose tissue and the vasculature
Fig. 4 Effects of chronic treatment with telmisartan on weight gain, food intake, serum parameters and fat pad weight in wild-type (WT) and PPAR-␦-deficient (PPAR-␦ Ϫ/-) mice. Mice were fed a regular diet (Cont) or regular diet plus telmisartan (Tel). (A), (B) Body weights were measured every 2 weeks throughout the experimental period. (C), Daily food intake per mouse was recorded during the first 10 days after the start of telmisartan administration. Fasting serum levels of glucose (D), insulin (E) and triglyceride (F) were examined using routine methods after 24 weeks' administration. (G) Subcutaneous fat (Sub-fat) and visceral fat (Vis-fat) were isolated and weighed when mice were killed after 24 weeks' administration. H The
Although telmisartan is regarded as a partial PPAR-␥ agonist [2] [4, 24, 25] . Activation of AMPK in skeletal muscle increases glucose uptake, fatty acid oxidation and mitochondrial biogenesis by increasing gene expression in these pathways [26] . Administration of PPAR-␦ agonist or AMPK agonist increased oxidative fibre content and running endurance [4, 5] . In this study, we showed that telmisartan promoted AMPK phospherylation through PPAR-␦ activation. A Post-exercise oxygen consumption is accompanied by an elevated consumption of fuel [28] . In response to exercise, fat stores are broken down and free fatty acids are released into the blood. In recovery, the direct oxidation of free fatty acids as fuel and the energy consuming reconversion of free fatty acids back into fat stores both take place [29] .
Although 
